WP
ARIA

WealthPLAN Partners’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

WealthPLAN Partners’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$534 Hold
40
– – ﹤0.01% 918
2016
Q2 		$296 Buy
+40
New +$300 ﹤0.01% 2392
2015
Q4 		$250 Buy
+40
New +$263 ﹤0.01% 1607
2015
Q2 		– Sell
-40
Closed – – 539
2015
Q1 		$0 Buy
+40
New +$296 ﹤0.01% 547

Other funds holding ARIA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

WealthPLAN Partners's ARIA Position: Q3 2016 in Review

WealthPLAN Partners held its Ariad Pharmaceuticals Inc (ARIA) position steady in Q3 2016 at 40 shares worth $534. The position accounts for ﹤0.01% of the portfolio, ranked #918.

WealthPLAN Partners first reported a position in ARIA in Q1 2015 and has held it in 4 quarters since. 203 funds tracked by Wall St. Rank hold ARIA as of Q3 2016.

  • WealthPLAN Partners held 40 shares of Ariad Pharmaceuticals Inc worth $534 as of Q3 2016.
  • WealthPLAN Partners left its Ariad Pharmaceuticals Inc share count unchanged in Q3 2016.
  • Ariad Pharmaceuticals Inc made up ﹤0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #918 holding.
  • WealthPLAN Partners first reported a position in Ariad Pharmaceuticals Inc in Q1 2015 and has held it in 4 quarters since.
  • 203 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.